I’ve decided to do an experiment and overview some new companies that I like. If you like the idea, I can do it 1-2 times per year. You can suggest new cool companies to me. In order to pick companies for this list, I relied on the following criteria:
- Related to stem cell research, regenerative medicine, cell therapy field (therapeutic, tools, reagents, service);
- New (0-5 years of existence) or relatively new and under-appreciated;
- Unique approach/ platform, which excites my interest.
1. MiroMatrix Medical
The first startup, aimed to commercialize organ decellularization in tissue engineering. University of Minnesota’s spin-off.
No web site. The first startup, commercializing biosutures. The company provides an unique approach to cell therapy delivery – via surgical threads. Worcester Polytechnic Institute’s spin-off. Read more here and here.
6. Wibi + Works
Pre-clinical stage company, commercializing mesenchymal stem cell-based therapies in diseases associated with inflammation. The unique approach allows to generate pro-inflammatory MSC1 and anti-inflammatory MSC2.
7. Editas Medicine
The first startup, aimed to commercialize genome editing by CRISPR/Cas methodology. Very impressive and unique techonology. Great leadership and foundation. MIT/ Harvard U spin-off. Three weeks ago, company has raised $43M to start.
Very recent Lonza’s spin-off. Provides large quantities of affordable clinical-grade mesenchymal stem cells for translational studies in regenerative medicine. Unique approach and expertise. Read more here.
9. Juno Therapeutics
Very new clinical-stage company, which is commercializing two approaches in immunocellular T-cell therapy of cancer (CAR and TCR). Very powerful leadership and foundation. Company has raised $120M in the first round of investment.
10. MitoGenome Therapeutics
No web site. The first company aimed to commercialize mtDNA replacement in oocytes to treat inherited mitochondrial diseases. The person behind of IP is Shoukhrat Mitalipov.
Disclaimer: This list reflects solely my opinion and sympathy. I have no financial interest in companies, mentioned in this post. This post should not be considered as financial advice.